Daily nursing for multiple myeloma: whole life cycle health management based on the doctor-nurse-patient integration model_West China Medical Journal

Authors：

SHEN Hongyu , TANG Wenjiao , CHEN Fengjiao , LENG Yamei ,  ZHANG Li , PAN Ling , NIU Ting

Department of Hematology, West China Hospital, Sichuan University / West China School of Nursing, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

ZHANG Li, Email: drzhangli2014@sina.com

Keywords：

Multiple myeloma; doctor-nurse-patient integration; whole life cycle health management; nursing

DOI：

10.7507/1002-0179.202310136

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

With the continuous development of new drugs and immunotherapy, the survival period of patient with multiple myeloma (MM) is continuously prolonged, and the disease is becoming chronic. Due to the involvement of multiple systems and numerous complications, the daily nursing for MM faces significant challenges. The doctor-nurse-patient integration model and the whole life cycle health management model for daily nursing of MM are expected to reduce the social burden related to diseases, improve patients’ quality of life, and reduce medical costs. This article provides a review on three aspects of MM doctor-nurse-patient integration, whole life cycle health management, and daily health management involving multiple systems.

Citation： SHEN Hongyu, TANG Wenjiao, CHEN Fengjiao, LENG Yamei, ZHANG Li, PAN Ling, NIU Ting. Daily nursing for multiple myeloma: whole life cycle health management based on the doctor-nurse-patient integration model. West China Medical Journal, 2025, 40(3): 490-494. doi: 10.7507/1002-0179.202310136 Copy

1.	Wang S, Xu L, Feng J, et al. Prevalence and Incidence of multiple myeloma in urban area in China: a national population-based analysis. Front Oncol, 2020, 9: 1513.
2.	Liu W, Liu J, Song Y, et al. Mortality of lymphoma and myeloma in China, 2004-2017: an observational study. J Hematol Oncol, 2019, 12(1): 22.
3.	陈雅姝, 刘敏, 徐晓旭, 等. 多发性骨髓瘤患者存活期的危险因素分析. 解放军预防医学杂志, 2019, 37(7): 78-79.
4.	唐荣芳, 董敏, 伍志梅, 等. 老年多发性骨髓瘤化疗病人医院感染特点及影响因素分析. 实用老年医学, 2020, 34(2): 125-129.
5.	Gay F, Engelhardt M, Terpos E, et al. From transplant to novel cellular therapies in multiple myeloma: European myeloma network guidelines and future perspectives. Haematologica, 2018, 103(2): 197-211.
6.	American Nurses Association. Nersing’s social policy statement. Washington DC: American Nurse’s Publishing, 1995: 104-108.
7.	沈晓, 张培庆, 李文霞, 等. 医护一体化护理对糖尿病住院患者血糖控制及遵医行为的影响. 国际护理学杂志, 2018, 37(7): 911-914.
8.	缪成君, 吴艳. 医护一体化健康教育对肺结核患者疾病认知水平及自我管理能力的影响. 医学临床研究, 2019, 36(12): 2490-2492.
9.	李一桔, 陈云霞, 陆萍, 等. 医护一体化模式对乳腺癌患者改良根治术后上肢功能训练自我效能及康复效果的影响. 医学临床研究, 2021, 38(3): 455-457.
10.	李德勤, 张瑾, 曹竹如, 等. 病房-门诊-家庭医护一体化管理对慢性肾脏病患者负性情绪和自我护理能力的影响. 安徽医学, 2021, 42(11): 1302-1305.
11.	国家卫生和计划生育委员会, 李斌. 《“健康中国 2030”规划纲要》辅导读本. 北京: 人民卫生出版社, 2017: 11-12.
12.	刘洁, 魏力. 全周期疾病管理对多发性骨髓瘤患者自我护理能力及并发症的影响. 天津护理, 2021, 29(2): 138-141.
13.	张艳, 杨敏. 基于医护一体化的延续性护理模式应用于多发性骨髓瘤患者的效果分析. 中西医结合护理(中英文), 2021, 7(2): 17-20.
14.	李玉军, 刘丽洋, 肖娟娟. 新诊断老年多发性骨髓瘤的预后分层及治疗进展. 实用肿瘤学杂志, 2022, 36(1): 84-88.
15.	Norful AA, de Jacq K, Carlino R, et al. Nurse practitioner-physician comanagement: a theoretical model to alleviate primary care strain. Ann Fam Med, 2018, 16(3): 250-256.
16.	段嘉宇, 崔健, 唐文娇, 等. 多发性骨髓瘤疾病全周期健康管理. 中国医学科学院学报, 2022, 44(4): 673-677.
17.	Ma L, Xu S, Qu J, et al. Monoclonal gammopathy of undetermined significance in Chinese population: a prospective epidemiological study. Hematol Oncol, 2019, 37(1): 75-79.
18.	魏宇君, 黄仲夏. 多发性骨髓瘤病情演变和早期诊断研究进展. 肿瘤学杂志, 2020, 26(2): 81-85.
19.	Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. Am Fam Physician, 2017, 95(6): 373-383.
20.	Langseth ØO, Myklebust TÅ, Johannesen TB, et al. Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017. Br J Haematol, 2020, 191(3): 418-425.
21.	Brigle K, Rogers B. Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs, 2017, 33(3): 225-236.
22.	吴菲, 单鹏, 贺学姣, 等. 15 例多发性骨髓瘤早期误诊临床探究及启示. 现代生物医学进展, 2020, 20(12): 2375-2379.
23.	Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol, 2020, 38(17): 1928-1937.
24.	Binder M, Rajkumar SV, Ketterling RP, et al. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer J, 2016, 6(3): e401.
25.	樊代明. 中国肿瘤整合诊治指南(CACA). 天津: 天津科学技术出版, 2022: 1926.
26.	Robak P, Drozdz I, Szemraj J, et al. Drug resistance in multiple myeloma. Cancer Treat Rev, 2018, 70: 199-208.
27.	Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB (alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol, 2017, 4(9): e431-e442.
28.	Landgren O, Kazandjian D. Modern myeloma therapy + sustained minimal residual disease-negative = (functional) cure!. J Clin Oncol, 2022, 40(25): 2863-2866.
29.	Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2017, 28(suppl 4): iv52-iv61.
30.	中国医师协会血液科医师分会, 中华医学会血液学分会. 中国多发性骨髓瘤诊治指南(2022 年修订). 中华内科杂志, 2022, 61(5): 480-487.
31.	闫宇辰, 李振宇. 复发难治性多发性骨髓瘤的临床研究进展. 徐州医科大学学报, 2022, 42(2): 148-151.
32.	郝牧, 邱录贵. 多发性骨髓瘤肿瘤生物学研究进展. 中国细胞生物学学报, 2022, 44(1): 111-119.
33.	中国临床肿瘤学会(CSCO)指南工作委员会. 多发性骨髓瘤骨病临床诊疗专家共识(2021). 临床肿瘤学杂志, 2022, 27(1): 65-72.
34.	李高, 张启科, 魏小芳, 等. 多发性骨髓瘤患者使用硼替佐米化疗期间发生肺部感染的临床危险因素分析. 中国实验血液学杂志, 2021, 29(1): 152-157.
35.	Zahid MF, Ali N, Nasir M, et al. Infections in patients with multiple myeloma treated with conventional chemotherapy: a single-center, 10-year experience in Pakistan. Hematol Transfus Cell Ther, 2019, 41(4): 292-297.
36.	Chen YK, Han SM, Yang Y, et al. Early mortality in multiple myeloma: experiences from a single institution. Hematology, 2016, 21(7): 392-398.
37.	Khan R, Apewokin S, Grazziutti M, et al. Renal insufficiency retains adverse prognostic implications despite renal function improvement following total therapy for newly diagnosed multiple myeloma. Leukemia, 2015, 29(5): 1195-201.
38.	Bozic B, Rutner J, Zheng C, et al. Advances in the treatment of relapsed and refractory multiple myeloma in patients with renal insufficiency: novel agents, immunotherapies and beyond. Cancers (Basel), 2021, 13(20): 5036.
39.	Mohyuddin GR, Koehn K, Shune L, et al. Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005-2019. Leuk Lymphoma, 2021, 62(6): 1386-1395.
40.	Mikhael J, Singh E, Rice MS. Real-world renal function among patients with multiple myeloma in the United States. Blood Cancer J, 2021, 11(5): 99.
41.	Faiman B. Diarrhea in multiple myeloma: a review of the literature. Clin J Oncol Nurs, 2016, 20(4): E100-E105.
42.	Hu X, Wang W, Wang Y, et al. Fear of cancer recurrence in patients with multiple myeloma: prevalence and predictors based on a family model analysis. Psychooncology, 2021, 30(2): 176-184.
43.	周鹏飞, 张瑾慧. 心理护理干预对多发性骨髓瘤患者疼痛及生活质量的影响. 中国肿瘤临床与康复, 2021, 28(10): 1259-1261.
44.	高佳, 孙叶飞. 癌症患者家庭照顾者复发恐惧的研究进展. 中华护理杂志, 2022, 57(7): 887-891.
45.	杨梅. 护理干预对多发性骨髓瘤患者疼痛、生活质量及心理评分的影响. 现代中西医结合杂志, 2021, 30(3): 320-323.

1. Wang S, Xu L, Feng J, et al. Prevalence and Incidence of multiple myeloma in urban area in China: a national population-based analysis. Front Oncol, 2020, 9: 1513.
2. Liu W, Liu J, Song Y, et al. Mortality of lymphoma and myeloma in China, 2004-2017: an observational study. J Hematol Oncol, 2019, 12(1): 22.
3. 陈雅姝, 刘敏, 徐晓旭, 等. 多发性骨髓瘤患者存活期的危险因素分析. 解放军预防医学杂志, 2019, 37(7): 78-79.
4. 唐荣芳, 董敏, 伍志梅, 等. 老年多发性骨髓瘤化疗病人医院感染特点及影响因素分析. 实用老年医学, 2020, 34(2): 125-129.
5. Gay F, Engelhardt M, Terpos E, et al. From transplant to novel cellular therapies in multiple myeloma: European myeloma network guidelines and future perspectives. Haematologica, 2018, 103(2): 197-211.
6. American Nurses Association. Nersing’s social policy statement. Washington DC: American Nurse’s Publishing, 1995: 104-108.
7. 沈晓, 张培庆, 李文霞, 等. 医护一体化护理对糖尿病住院患者血糖控制及遵医行为的影响. 国际护理学杂志, 2018, 37(7): 911-914.
8. 缪成君, 吴艳. 医护一体化健康教育对肺结核患者疾病认知水平及自我管理能力的影响. 医学临床研究, 2019, 36(12): 2490-2492.
9. 李一桔, 陈云霞, 陆萍, 等. 医护一体化模式对乳腺癌患者改良根治术后上肢功能训练自我效能及康复效果的影响. 医学临床研究, 2021, 38(3): 455-457.
10. 李德勤, 张瑾, 曹竹如, 等. 病房-门诊-家庭医护一体化管理对慢性肾脏病患者负性情绪和自我护理能力的影响. 安徽医学, 2021, 42(11): 1302-1305.
11. 国家卫生和计划生育委员会, 李斌. 《“健康中国 2030”规划纲要》辅导读本. 北京: 人民卫生出版社, 2017: 11-12.
12. 刘洁, 魏力. 全周期疾病管理对多发性骨髓瘤患者自我护理能力及并发症的影响. 天津护理, 2021, 29(2): 138-141.
13. 张艳, 杨敏. 基于医护一体化的延续性护理模式应用于多发性骨髓瘤患者的效果分析. 中西医结合护理(中英文), 2021, 7(2): 17-20.
14. 李玉军, 刘丽洋, 肖娟娟. 新诊断老年多发性骨髓瘤的预后分层及治疗进展. 实用肿瘤学杂志, 2022, 36(1): 84-88.
15. Norful AA, de Jacq K, Carlino R, et al. Nurse practitioner-physician comanagement: a theoretical model to alleviate primary care strain. Ann Fam Med, 2018, 16(3): 250-256.
16. 段嘉宇, 崔健, 唐文娇, 等. 多发性骨髓瘤疾病全周期健康管理. 中国医学科学院学报, 2022, 44(4): 673-677.
17. Ma L, Xu S, Qu J, et al. Monoclonal gammopathy of undetermined significance in Chinese population: a prospective epidemiological study. Hematol Oncol, 2019, 37(1): 75-79.
18. 魏宇君, 黄仲夏. 多发性骨髓瘤病情演变和早期诊断研究进展. 肿瘤学杂志, 2020, 26(2): 81-85.
19. Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. Am Fam Physician, 2017, 95(6): 373-383.
20. Langseth ØO, Myklebust TÅ, Johannesen TB, et al. Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017. Br J Haematol, 2020, 191(3): 418-425.
21. Brigle K, Rogers B. Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs, 2017, 33(3): 225-236.
22. 吴菲, 单鹏, 贺学姣, 等. 15 例多发性骨髓瘤早期误诊临床探究及启示. 现代生物医学进展, 2020, 20(12): 2375-2379.
23. Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol, 2020, 38(17): 1928-1937.
24. Binder M, Rajkumar SV, Ketterling RP, et al. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer J, 2016, 6(3): e401.
25. 樊代明. 中国肿瘤整合诊治指南(CACA). 天津: 天津科学技术出版, 2022: 1926.
26. Robak P, Drozdz I, Szemraj J, et al. Drug resistance in multiple myeloma. Cancer Treat Rev, 2018, 70: 199-208.
27. Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB (alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol, 2017, 4(9): e431-e442.
28. Landgren O, Kazandjian D. Modern myeloma therapy + sustained minimal residual disease-negative = (functional) cure!. J Clin Oncol, 2022, 40(25): 2863-2866.
29. Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2017, 28(suppl 4): iv52-iv61.
30. 中国医师协会血液科医师分会, 中华医学会血液学分会. 中国多发性骨髓瘤诊治指南(2022 年修订). 中华内科杂志, 2022, 61(5): 480-487.
31. 闫宇辰, 李振宇. 复发难治性多发性骨髓瘤的临床研究进展. 徐州医科大学学报, 2022, 42(2): 148-151.
32. 郝牧, 邱录贵. 多发性骨髓瘤肿瘤生物学研究进展. 中国细胞生物学学报, 2022, 44(1): 111-119.
33. 中国临床肿瘤学会(CSCO)指南工作委员会. 多发性骨髓瘤骨病临床诊疗专家共识(2021). 临床肿瘤学杂志, 2022, 27(1): 65-72.
34. 李高, 张启科, 魏小芳, 等. 多发性骨髓瘤患者使用硼替佐米化疗期间发生肺部感染的临床危险因素分析. 中国实验血液学杂志, 2021, 29(1): 152-157.
35. Zahid MF, Ali N, Nasir M, et al. Infections in patients with multiple myeloma treated with conventional chemotherapy: a single-center, 10-year experience in Pakistan. Hematol Transfus Cell Ther, 2019, 41(4): 292-297.
36. Chen YK, Han SM, Yang Y, et al. Early mortality in multiple myeloma: experiences from a single institution. Hematology, 2016, 21(7): 392-398.
37. Khan R, Apewokin S, Grazziutti M, et al. Renal insufficiency retains adverse prognostic implications despite renal function improvement following total therapy for newly diagnosed multiple myeloma. Leukemia, 2015, 29(5): 1195-201.
38. Bozic B, Rutner J, Zheng C, et al. Advances in the treatment of relapsed and refractory multiple myeloma in patients with renal insufficiency: novel agents, immunotherapies and beyond. Cancers (Basel), 2021, 13(20): 5036.
39. Mohyuddin GR, Koehn K, Shune L, et al. Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005-2019. Leuk Lymphoma, 2021, 62(6): 1386-1395.
40. Mikhael J, Singh E, Rice MS. Real-world renal function among patients with multiple myeloma in the United States. Blood Cancer J, 2021, 11(5): 99.
41. Faiman B. Diarrhea in multiple myeloma: a review of the literature. Clin J Oncol Nurs, 2016, 20(4): E100-E105.
42. Hu X, Wang W, Wang Y, et al. Fear of cancer recurrence in patients with multiple myeloma: prevalence and predictors based on a family model analysis. Psychooncology, 2021, 30(2): 176-184.
43. 周鹏飞, 张瑾慧. 心理护理干预对多发性骨髓瘤患者疼痛及生活质量的影响. 中国肿瘤临床与康复, 2021, 28(10): 1259-1261.
44. 高佳, 孙叶飞. 癌症患者家庭照顾者复发恐惧的研究进展. 中华护理杂志, 2022, 57(7): 887-891.
45. 杨梅. 护理干预对多发性骨髓瘤患者疼痛、生活质量及心理评分的影响. 现代中西医结合杂志, 2021, 30(3): 320-323.

Previous Article
Application of artificial intelligence in deep brain stimulation therapy
Next Article
Impact of large language model ChatGPT on medical research

West China Medical Journal

Daily nursing for multiple myeloma: whole life cycle health management based on the doctor-nurse-patient integration model

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content